| Government health expenditures and health outcomes FAS Bokhari, Y Gai, P Gottret Health economics 16 (3), 257-273, 2007 | 470 | 2007 |
| School accountability laws and the consumption of psychostimulants FAS Bokhari, H Schneider Journal of Health Economics 30 (2), 355-372, 2011 | 69 | 2011 |
| An analysis of the significant variation in psychostimulant use across the US F Bokhari, R Mayes, RM Scheffler Pharmacoepidemiology and Drug Safety 14 (4), 267-275, 2005 | 67 | 2005 |
| Attention-deficit/hyperactivity disorder in children: excess costs before and after initial diagnosis and treatment cost differences by ethnicity GT Ray, P Levine, LA Croen, FAS Bokhari, T Hu, LA Habel Archives of pediatrics & adolescent medicine 160 (10), 1063-1069, 2006 | 66 | 2006 |
| OPEN VERSUS CLOSED FIRMS AND THE DYNAMICS OF INDUSTRY EVOLUTION* A Arora, FAS Bokhari The Journal of Industrial Economics 55 (3), 499-527, 2007 | 61* | 2007 |
| Entry in the ADHD drugs market: Welfare impact of generics and me‐too's FAS Bokhari, GM Fournier The Journal of industrial economics 61 (2), 339-392, 2013 | 60 | 2013 |
| Managed care competition and the adoption of hospital technology: The case of cardiac catheterization FAS Bokhari International Journal of Industrial Organization 27 (2), 223-237, 2009 | 41* | 2009 |
| Risk factors for discontinuing drug therapy among children with ADHD FAS Bokhari, F Heiland, P Levine, GT Ray Health Services and Outcomes Research Methodology 8, 134-158, 2008 | 19 | 2008 |
| Assessing the impact of health care expenditures on mortality using cross-country data R Nakamura, J Lomas, K Claxton, F Bokhari, R Moreno-Serra, M Suhrcke Global Health Economics: Shaping Health Policy In Low-And Middle-income …, 2020 | 16 | 2020 |
| WHO.(2000) S Anand, M Ravaillion, P Berman, F Bokhari, Y Gai, P Gottret, D Cutler, ... World Health Report: Health Systems Improving Performance. Geneva: World …, 0 | 15 | |
| Demand estimation and merger simulations for drugs: Logits v. AIDS FAS Bokhari, F Mariuzzo International Journal of Industrial Organization 61, 653-685, 2018 | 14 | 2018 |
| Entry limiting agreements: First‐mover advantage, authorized generics, and pay‐for‐delay deals FAS Bokhari, F Mariuzzo, A Polanski Journal of Economics & Management Strategy 29 (3), 516-542, 2020 | 13* | 2020 |
| What is the price of pay-to-delay deals? FAS Bokhari Journal of Competition Law and Economics 9 (3), 739-753, 2013 | 13 | 2013 |
| Discrimination in healthcare: A field experiment with Pakistan's transgender community HF Ahmad, S Banuri, F Bokhari Labour Economics 87, 102490, 2024 | 7 | 2024 |
| Innovation and growth in the UK pharmaceuticals: the case of product and marketing introductions FAS Bokhari, F Mariuzzo, AR Bennato Small Business Economics 57 (1), 603-634, 2021 | 5 | 2021 |
| Selective admission into stroke unit and patient outcomes: a tale of four cities FAS Bokhari, I Wellwood, AG Rudd, P Langhorne, MS Dennis, CDA Wolfe Health economics review 4, 1-10, 2014 | 5 | 2014 |
| Banning volume discounts to curb excessive consumption: A cautionary tale FAS Bokhari, PW Dobson, M Morciano, M Suhrcke European Economic Review 156, 104480, 2023 | 4 | 2023 |
| Product line extensions under the threat of entry: evidence from the UK pharmaceuticals market FAS Bokhari, W Yan Available at SSRN 3675109, 2020 | 4 | 2020 |
| Rise of ADHD prevalence and psychostimulant use: A historical perspective R Mayes, F Bokhari 130th Annual Meeting of APHA, Abstract 46109, 2002 | 4 | 2002 |
| Antibacterial resistance and the cost of affecting demand: The case of uk antibiotics FAS Bokhari, F Mariuzzo, W Yan International Journal of Industrial Organization, 103082, 2024 | 3 | 2024 |
Franco MariuzzoUniversity of East AngliaVerified email at uea.ac.uk
